<DOC>
	<DOCNO>NCT00776230</DOCNO>
	<brief_summary>The objective ass immunogenicity commercial IC51 batch 3 different time point post filling ( 12 , 18 , 24 month ) term Geometric Mean Titers ( GMT ) anti-JEV neutralizing antibody Day 56 first vaccination .</brief_summary>
	<brief_title>Immunogenicity Commercial Batch JEV IC51 24 Months Post Filling</brief_title>
	<detailed_description>Open‐label , multicenter , phase 3 study assess immunogenicity various time point throughout shelf‐life commercial batch IC51 ( Batch IC51/07F/008 ) The study population consist male female healthy subject , age least 18 year . The study perform 3 study center Germany Austria . Three sequential cohort , contain 100 subject , enrol study approximately 12 , 18 24 month fill commercial batch IC51/07F/008 IC51</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female healthy adult age least 18 year write informed consent either childbearing potential negative pregnancy test . History immunodeficiency immunosuppressive therapy , know HIV infection , drug addiction include alcohol dependence , prior vaccination JE</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>